X-ray vendor Trex Medical (Hall A, #3500) has completed the clinical trials required for a regulatory submission of its full-field digital mammography detector and is planning to submit a 510(k) filing for the product some time around the RSNA show,
X-ray vendor Trex Medical (Hall A, #3500) has completed the clinical trials required for a regulatory submission of its full-field digital mammography detector and is planning to submit a 510(k) filing for the product some time around the RSNA show, according to Hal Kirshner, CEO and president of the Danbury, CT, company. Trex plans to offer the CCD-based detectors as retrofits to installed Lorad and Bennett mammography units.
Trex will display the latest clinical images acquired with the detectors at multicenter clinical trials used to support the FDA filing. In the trials, 520 patients were examined, and the studies were being read in the weeks up to the RSNA conference. Clinicians participating in the trials will also be present to discuss their findings.
Farther down the product pipeline are flat-panel digital detectors, which Trex will display in its RSNA booth as works-in-progress for general radiographic systems manufactured by its Bennett and Continental subsidiaries. In addition to static x-ray studies, Trex plans to develop versions for fluoroscopy and cardiac cath applications, and will show a demonstration of the panels used for 30 fps imaging.
The flat-panel devices are about a year from a regulatory submission, Kirshner said. Trex also plans to develop a flat-panel digital mammography detector, although that project is not as urgent because the company's CCD-based product is about to reach the market.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.